Role of mTORC1 and mTORC2 in Breast Cancer: Therapeutic Targeting of mTOR and Its Partners to Overcome Metastasis and Drug Resistance.

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Advances in Experimental Medicine and Biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-3-030-20301-6_15PMID 31456190
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic effects of inhibiting the MNK-eIF4E and PI3K/AKT/ mTOR pathways on cell migration in MDA-MB-231 cells

  2018cited by this paper
• Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway

  2018cited by this paper
• Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells

  2018cited by this paper
• Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

  2018cited by this paper
• MicroRNA-10a suppresses breast cancer progression via PI3K/Akt/mTOR pathway

  2017cited by this paper
• Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis

  2017cited by this paper
• Gold nanoparticles–conjugated quercetin induces apoptosis via inhibition of EGFR/PI3K/Akt–mediated pathway in breast cancer cell lines (MCF‐7 and MDA‐MB‐231)

  2017cited by this paper
• Eriocalyxin B, a novel autophagy inducer, exerts anti‐tumor activity through the suppression of Akt/mTOR/p70S6K signaling pathway in breast cancer

  2017cited by this paper
• Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.

  2016cited by this paper
• MicroRNA-147 suppresses proliferation, invasion and migration through the AKT/mTOR signaling pathway in breast cancer.

  2016cited by this paper
• Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

  2016cited by this paper
• Rapamycin Loaded Solid Lipid Nanoparticles as a New Tool to Deliver mTOR Inhibitors: Formulation and in Vitro Characterization

  2016cited by this paper
• miR‐199a‐5p regulates β1 integrin through Ets‐1 to suppress invasion in breast cancer

  2016cited by this paper
• Rational Design of Multifunctional Dendritic Mesoporous Silica Nanoparticles to Load Curcumin and Enhance Efficacy for Breast Cancer Therapy.

  2016cited by this paper
• Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer

  2016cited by this paper
• MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene

  2015cited by this paper
• Secalonic Acid-D Represses HIF1α/VEGF-Mediated Angiogenesis by Regulating the Akt/mTOR/p70S6K Signaling Cascade.

  2015cited by this paper
• Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy.

  2015cited by this paper
• AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis

  2015cited by this paper
• Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells.

  2015cited by this paper
• mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation

  2015cited by this paper
• Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.

  2014cited by this paper
• microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity

  2014cited by this paper
• Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death

  2014cited by this paper
• Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells.

  2014cited by this paper
• Anthricin Isolated from Anthriscus sylvestris (L.) Hoffm. Inhibits the Growth of Breast Cancer Cells by Inhibiting Akt/mTOR Signaling, and Its Apoptotic Effects Are Enhanced by Autophagy Inhibition

  2013cited by this paper
• mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo

  2012cited by this paper

• Single-Cell RNA and ATAC Sequencing Reveal Cellular Heterogeneity and Chromatin Accessibility Dynamics in Young Chinese Breast Cancer Patients across Pre- and Post-Neoadjuvant Therapy

  2025cites this paper
• The endocrine and epigenetic impact of persistent cow milk consumption on prostate carcinogenesis

  2022cites this paper
• Ras-mediated activation of mTORC2 promotes breast epithelial cell migration and invasion

  2022cites this paper
• Therapeutic silencing of mTOR by systemically administered siRNA-loaded neutral liposomal nanoparticles inhibits DMBA-induced mammary carcinogenesis

  2022cites this paper
• Recent advances of the mammalian target of rapamycin signaling in mesenchymal stem cells

  2022cites this paper
• Effects of Induced Exosomes from Endometrial Cancer Cells on Tumor Activity in the Presence of Aurea helianthus Extract

  2021cites this paper
• Clinical and genomic characteristics of metabolic syndrome in colorectal cancer

  2021cites this paper
• Lifetime Impact of Cow’s Milk on Overactivation of mTORC1: From Fetal to Childhood Overgrowth, Acne, Diabetes, Cancers, and Neurodegeneration

  2021cites this paper
• A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers.

  2021cites this paper
• Circulating non-coding RNAs as a diagnostic and management biomarker for breast cancer: current insights

  2021cites this paper
• Bisdemethoxycurcumin Promotes Apoptosis and Inhibits the Epithelial-Mesenchymal Transition through the Inhibition of the G-Protein-Coupled Receptor 161/Mammalian Target of Rapamycin Signaling Pathway in Triple Negative Breast Cancer Cells.

  2021cites this paper
• MAP3K1 SNP rs889312 potential risk and MAP3K9 SNP rs11628333 menopause dependent association for breast cancer

  2021cites this paper
• Insight into the divergent role of TRAIL in non‐neoplastic neurological diseases

  2020cites this paper
• Cancer stem cell property and gene signature in bone-metastatic Breast Cancer cells

  2020cites this paper
• Plasma Extracellular Vesicle Long RNA Pro�les in the Diagnosis and Prediction of Treatment Response for Breast Cancer

  2020cites this paper
• A systematic review and meta-analysis protocol of clinical characteristics and prognostic significance of mammalian target of rapamycin for gastric cancer patients

  2020cites this paper
• Modulation of Tumor Microenvironment through Aurea Helianthus Extract and Induced Exosomes

  2020cites this paper
• Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer

  2020cites this paper
• Transcriptional co-activators YAP/TAZ: Potential therapeutic targets for metastatic breast cancer.

  2020cites this paper
• Ras, PI3K and mTORC2 – three's a crowd?

  2020cites this paper
• Research progress on mechanism of autophagy regulatory factor mTOR in myocardial ischemia-reperfusion injury

  2020cites this paper
• Linc‐ROR promotes the progression of breast cancer and decreases the sensitivity to rapamycin through miR‐194‐3p targeting MECP2

  2020cites this paper